Kevin Pan, CEO of Asieris, shares the origins behind the company’s distinctive name and how it reflects their ambition to bridge scientific discoveries and innovative medicines; their focus on genitourinary (GU) tumours and related disease because of the significant and oft-overlooked medical needs there; and the importance of building and maintaining strong KOL and other stakeholder networks to position themselves as an innovation leader in their therapeutic area.
We hope Asieris can bridge [China and the US] and synergize all their advantages to build an outstanding company with great products
